PubMed Health⌕ Search

Biomedical subjects

M V Croce

Publications and source records attributed to M V Croce.

26 records · Page 2Linked to original sources
PubMed1984

Correlation of immune complexes with serum cytotoxic activity induced by antisperm cytophilic antibodies.

The object of the present work was to investigate: a) The cytotoxic activity of cytophilic antibody in sera from guinea pigs sensitized with the testicular antigen; b) The presence of immune complexes. In vitro cytotoxicity induced by hyperimmune sera or by the cytophilic antibodies eluted from the corresponding macrophages, was demonstrated after incubation with either germinal cells or spermatozoa. Marked cytotoxicity was also observed in vivo when sera or antibodies were injected into the tests, as shown by sequential histologic studies. Circulating immune complexes, as tested by the 125I-C1q binding assay, were not detected in these sera. On the contrary, high levels of circulating immune complexes were found when the polyethyleneglycol precipitation test was used. It can be concluded that the cytotoxic effect induced by cytophilic antibodies of IgG2 nature, may be associated with polyethyleneglycol precipitating immune complexes.

Animals↗
PubMed1983

Antibodies presumably cross-reacting with mouse retrovirus type B and C in the sera of both leukemia-lymphoma and mammary cancer patients.

In the mouse, retrovirus B and C are causal agents of mammary cancer and leukemia, respectively. In previous work it was demonstrated that sera of leukemia-lymphoma patients possess antibodies which react with antigenic determinants of Type C virus present on AKR-lymphoma and AKR-thymus targets. The object of this paper was to determine whether these antibodies also reacted with Type B viral antigens present on a virus-induced BALB-mammary carcinoma; at the same time a comparative study was carried out with sera of breast cancer patients. A total of 325 sera were obtained from 277 leukemia-lymphoma cases under protocol treatment: 232 acute lymphoid leukemia, 23 acute myeloid leukemia, 15 chronic myeloid leukemia and 55 Hodgkin lymphoma sera. A total of 240 sera were obtained from breast cancer patients at the time of diagnosis and 196 sera from normal blood donors served as controls. Using indirect immunofluorescence with labeled anti-human IgG and the murine targets, antibodies were encountered in a high percentage of cancer cases and were consistently absent in normal sera. The results confirm the presence of antibodies reacting with murine Type C virus in leukemia-lymphoma cases and indicate the presence of antibodies reacting to both Type B and C retroviruses in the sera of breast cancer patients.

Animals↗
PubMedDate not supplied

Detection of circulating mammary mucin (Muc1) and MUC1 immune complexes (Muc1-CIC) in healthy women.

There is convincing epidemiological evidence that multiparity provides protection against the development of breast cancer. In the present study we evaluated the levels of MUC1 and MUC1 circulating immune complexes (MUC1-CIC) in 135 serum samples obtained from healthy women. The study population included 13 women who had never been pregnant, 31 primiparous pregnant women, 36 multiparous pregnant women who had lactated, 5 multiparous pregnant women who had never lactated, 24 multiparous non-pregnant women who were lactating at the time of the study, 24 multiparous non-pregnant women who had lactated, and 2 multiparous non-pregnant women who had never lactated. The purpose of this work was to detect MUC1 variations during pregnancy and lactation as well as to study the possible induction of a humoral immune response against MUC1 in these conditions. We employed ELISA techniques to measure MUC1 (CASA test) and MUC1-CIC (IgM and IgG) using two anti-MUC1 monoclonal antibodies (MAbs): C595 and SM3. Statistical analysis was performed using the ANOVA test. The pooled results pertaining to pregnant versus non-pregnant women were compared and significant differences were observed in MUC1 and MUC1-CIC-lgM levels detected with both MAbs; the MUC1-CIC-lgG levels detected with C595 were increased in the pregnant group while the MUC1-CIC-lgG levels detected with SM3 did not show any significant differences. When the results were compared between lactating and non-lactating women, no significant differences were found. In conclusion, MUC1 and MUC1-CIC-lgM, detected with both MAbs, and MUC1-CIC-4gG levels detected with the MAb C595 are apparently induced by pregnancy.

Adult↗
PubMedDate not supplied

Immune complexes in human malignant tumours. A review.

This paper is a review on immune complexes in malignant tumours. High levels of immune complexes have been detected in the serum of patients with malignant solid tumours, leukemias and lymphomas. These studies were performed using non-specific methods. Results obtained by different laboratories are in general coincident; elevated levels of immune complexes in pre-treatment samples and in recurrent disease and, normal values in post-treatment studies indicating a disease free state. Nevertheless, there are certain variations among the results obtained by different techniques suggesting the necessity to check various methods for each tumour type. Although there is no clear evidence that immune complexes in cancer patients contain tumor related products, the current status of clinical research suggests the potential of circulating immune complexes assays for monitoring malignant diseases.

Animals↗
PubMedDate not supplied

Breast cancer associated mucin: a review.

Breast mucins are expressed by malignant epithelial cells and they elicit an immune reaction. The up-regulation of mucin expression is association with tumour invasion, this mucin called MUC-1 reduces the cell-cell interaction facilitating cell detachment. The MUC-1 gene product, known as polymorphic epithelial mucin is a transmembrane high molecular weight glycoprotein. The molecule of MUC-1 has a central polypeptidic core with a carbohydrate linked in O-linkage to serines and threonines. The carbohydrate side chain epitope of MUC-1 molecule produced by breast cancer cells is heavily sialylated, giving their physical properties and increasing their immunogenicity. The development of monoclonal antibodies (MAb) has led to study the MUC-1 in subcellular extracts, tissues and culture supernatants from breast cancer and also colorectal carcinoma. The pattern of tumour cell staining with labeled MAb varies according with the grade of malignancy; these MAb bind either to peptide sequence and/or to the glycosylated epitopes. MUC-1 has a clinical relevance because serum concentrations may be useful for monitoring the response to therapy and progress of disease. MUC-1 epitope masking has been described since specific antibodies can combine with them forming immune complexes. Finally, mucins have been considered to develop vaccines against cancer, targeting specific carbohydrate and mucin epitopes.

Antibodies, Monoclonal↗
PubMedDate not supplied

Expression of tumour associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative immunohistochemical study.

Breast carcinoma cells may express a variety of clinically relevant epitopes, some of which are associated with aberrant glycosylation of MUC1 mucin molecules, as well as determinants which are commonly expressed on their normal molecular counterparts. The present investigation is primarily an immunochemical analysis of MUC1 epitopes and other tumour associated antigenic determinants, as defined by their reaction with monoclonal antibodies and expressed in normal, benign and malignant epithelia. It was determined that malignant tissues of the breast expressed MUC1 mucin, as well as the Le(y) hapten and CEA, at different intensities, cellular distribution and patterns and percentages of positively stained cells. Conversely, benign tissues expressed a low intensity of MUC1 which was restricted to apical cell surface membranes and lumen debris; a similar pattern was found in some normal breast sections. It was concluded that MUC1 mucin exhibits heterogeneous antigenicity (as defined by its reactivity with a panel of related anti-MUC1 monoclonal antibodies) which is predominantly related to the progression of malignant disease. Le(y) is a marker of breast neoplasia, while CEA was found on only a small proportion of tumours. These immunohistochemical findings are considered in the context of improving breast cancer diagnosis and therapy.

Antibodies, Monoclonal↗